Table 2.
Baseline information - Mild Cognitive Impairment (MCI)
| Amyloid | n | All (n = 611) | Amyloid positive (n = 377) | Amyloid negative (n = 234) | statistics |
| Age: mean (SD) years | 610 | 72.5 ( 7.4) | 73.5 ( 6.8) | 70.9 ( 8.1) | t = -4.0,df = 481.4,p = < .0001 * |
| Baseline MMSE | 611 | 27.8 ( 1.8) | 27.4 ( 1.8) | 28.4 ( 1.5) | t = 8.2,df = 630.7,p = < .0001 * |
| ApoE4 carrier status | 611 | 300 ( 49.1%) | 246 ( 65.3%) | 54 ( 23.1%) | ChiSq = 102.8,df = 1.0,p = < .0001 * |
| Baseline Hippocampus Volume (mm3) | 611 | 6865 (1133) | 6631 (1064) | 7242 (1142) | t = 6.6,df = 474.7,p = < .0001 * |
| Female gender: n (%) | 611 | 255 ( 41.7%) | 156 ( 41.4%) | 99 ( 42.3%) | ChiSq = 0.1, df = 1.0, p = 0.8210 |
| Higher CAIDE score: n (%) | 606 | 223 ( 36.8%) | 141 ( 37.8%) | 82 ( 35.2%) | ChiSq = 0.4, df = 1.0, p = 0.5172 |
| CAIDE Total Score | 606 | 5.9 ( 1.4) | 5.8 ( 1.4) | 5.9 ( 1.5) | t = 0.8, df = 543.7, p = 0.4211 |
| Depression as risk: n (%) | 611 | 192 ( 31.4%) | 110 ( 29.2%) | 82 ( 35.0%) | ChiSq = 2.3, df = 1.0, p = 0.1290 |
| Smokers: n (%) | 576 | 70 ( 12.2%) | 48 ( 13.5%) | 22 ( 10.0%) | ChiSq = 1.5, df = 1.0, p = 0.2138 |
| Follow-up time: median(IQR) | 611 | 48 ( 30- 78) | 48 ( 24- 60) | 48 ( 36- 96) | ChiSq = 17.8,df = 1.0,p = < .0001 * |
| Progression to dementia: n(%) | 611 | 221 ( 36.2%) | 195 ( 51.7%) | 26 ( 11.1%) | ChiSq = 103.2,df = 1.0,p = < .0001 * |
| p-tau181 | n | All (n = 551) | p-tau181 positive (n = 305) | p-tau181 negative (n = 246) | statistics |
| Age: mean (SD) years | 551 | 72.4 ( 7.5) | 73.4 ( 7.4) | 71.1 ( 7.4) | t = -3.4,df = 563.7,p = 0.0007 * |
| Baseline MMSE | 551 | 27.7 ( 1.8) | 27.4 ( 1.8) | 28.1 ( 1.7) | t = 5.2,df = 578.7,p = < .0001 * |
| ApoE4 carrier status | 551 | 273 ( 49.5%) | 192 ( 63.0%) | 81 ( 32.9%) | ChiSq = 49.1,df = 1.0,p = < .0001 * |
| Baseline Hippocampus Volume (mm3) | 551 | 6820 (1150) | 6582 (1077) | 7116 (1171) | t = 5.5,df = 504.2,p = < .0001 * |
| Female gender: n (%) | 551 | 230 ( 41.7%) | 132 ( 43.3%) | 98 ( 39.8%) | ChiSq = 0.7, df = 1.0, p = 0.4155 |
| Higher CAIDE score: n (%) | 548 | 196 ( 35.8%) | 102 ( 33.7%) | 94 ( 38.4%) | ChiSq = 1.3, df = 1.0, p = 0.2534 |
| CAIDE Total Score | 548 | 5.8 ( 1.4) | 5.7 ( 1.3) | 6.0 ( 1.5) | t = 2.2, df = 522.8, p = 0.0309 |
| Depression as risk: n (%) | 551 | 183 ( 33.2%) | 90 ( 29.5%) | 93 ( 37.8%) | ChiSq = 4.2, df = 1.0, p = 0.0398 |
| Smokers: n (%) | 551 | 68 ( 12.3%) | 41 ( 13.4%) | 27 ( 11.0%) | ChiSq = 0.8, df = 1.0, p = 0.3814 |
| Follow-up time: median(IQR) | 551 | 48 ( 36- 84) | 48 ( 36- 66) | 48 ( 36- 90) | ChiSq = 12.6,df = 1.0, p = 0.0004 * |
| Progression to dementia: n (%) | 551 | 213 ( 38.7%) | 163 ( 53.4%) | 50 ( 20.3%) | ChiSq = 63.0,df = 1.0,p = < .0001 * |
| Amyloid and p-tau181 | n | All (n = 418) | Amyloid and p-tau181 positive (n = 257) | Amyloid and p-tau181 negative (n = 160) | statistics |
| Age: mean (SD) years | 417 | 72.1 ( 7.6) | 73.4 ( 7.1) | 69.9 ( 7.8) | t = -4.4,df = 343.3, p = < .0001 * |
| Baseline MMSE | 417 | 27.7 ( 1.8) | 27.3 ( 1.8) | 28.4 ( 1.5) | t = 7.3,df = 419.3, p = < .0001 * |
| ApoE4 carrier status | 417 | 213 ( 51.1%) | 177 ( 68.9%) | 36 ( 22.5%) | ChiSq = 84.9,df = 1.0, p = < .0001 * |
| Baseline Hippocampus Volume (mm3) | 417 | 6763 (1142) | 6477 (1026) | 7221 (1174) | t = 6.6,df = 303.4, p = < .0001 * |
| Female gender: n (%) | 417 | 184 ( 44.1%) | 113 ( 44.0%) | 71 ( 44.4%) | ChiSq = 0.0, df = 1.0, p = 0.9353 |
| Higher CAIDE score: n (%) | 414 | 144 ( 34.8%) | 88 ( 34.5%) | 56 ( 35.2%) | ChiSq = 0.0, df = 1.0, p = 0.8827 |
| CAIDE Total Score | 414 | 5.8 ( 1.4) | 5.7 ( 1.3) | 5.9 ( 1.6) | t = 1.3, df = 332.2, p = 0.2014 |
| Depression as risk: n (%) | 417 | 144 ( 34.5%) | 78 ( 30.4%) | 66 ( 41.3%) | ChiSq = 5.2, df = 1.0, p = 0.0228 |
| Smokers: n (%) | 417 | 45 ( 10.8%) | 33 ( 12.8%) | 12 ( 7.5%) | ChiSq = 2.9, df = 1.0, p = 0.0874 |
| Follow-up time: median(IQR): | 417 | 48 ( 36- 78) | 48 ( 36- 60) | 60 ( 36- 96) | ChiSq = 20.7,df = 1.0, p = < .0001 * |
| Progression to dementia: n (%) | 417 | 178 ( 42.7%) | 158 ( 61.5%) | 20 ( 12.5%) | ChiSq = 96.7,df = 1.0, p = < .0001 * |
CU Cognitively Unimpaired, MCI Mild Cognitive Impairment, MMSE Mini-Mental State Examination, ApoE4 Apolipoprotein E epsilon 4 carriers, CAIDE Cardiovascular Risk Factors, Aging, and Dementia, p-tau181 Phosphorylated tau 181, CSF Cerebrospinal Fluid, n Number of participants, SD Standard Deviation, IQR Interquartile Range, ChiSq Chi-Square Test, df Degrees of Freedom, p p-value
*p-values indicate significant differences between biomarker positives and negatives (after correction for multiple comparisons p < 0.05/11, where 11 is the number of parameters compared), and are based on T-tests or Wilcoxon tests (follow-up time) in case of continuous variables and Chi-Square tests in case of categorical variables